5GZR

Zika virus E protein complexed with a neutralizing antibody Z23-Fab

Summary for 5GZR

• Entry DOI: 10.2210/pdb5gzr/pdb
• EMDB information: 9542
• Descriptor: structural protein E, strutural protein M, Z23 Fab heavy chain, ... (4 entities in total)
• Functional Keywords: zika virus, neutralizing antibody, single particle reconstruction, virus
• Biological source: Homo sapiens (Human); More
• Cellular location: Virion membrane ; Multi-pass membrane protein : A0A024B7W1 A0A024B7W1
• Total number of polymer chains: 10
• Total formula weight: 282689.53

Authors

Gao, G.G.,Shi, Y.,Peng, R.,Liu, S. (deposition date: 2016-10-01, release date: 2016-11-30, Last modification date: 2024-03-27)

Primary citation

Wang, Q.,Yang, H.,Liu, X.,Dai, L.,Ma, T.,Qi, J.,Wong, G.,Peng, R.,Liu, S.,Li, J.,Li, S.,Song, J.,Liu, J.,He, J.,Yuan, H.,Xiong, Y.,Liao, Y.,Li, J.,Yang, J.,Tong, Z.,Griffin, B.D.,Bi, Y.,Liang, M.,Xu, X.,Qin, C.,Cheng, G.,Zhang, X.,Wang, P.,Qiu, X.,Kobinger, G.,Shi, Y.,Yan, J.,Gao, G.F.
Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus
Sci Transl Med, 8:369ra179-369ra179, 2016

PubMed Abstract: The 2015-2016 outbreak of Zika virus (ZIKV) disease has affected many countries and is a major public health concern. ZIKV is associated with fetal microcephaly and neurological complications, and countermeasures are needed to treat and prevent ZIKV infection. We report the isolation of 13 specific human monoclonal antibodies from a single patient infected with ZIKV. Two of the isolated antibodies (Z23 and Z3L1) demonstrated potent ZIKV-specific neutralization in vitro without binding or neutralizing activity against strains 1 to 4 of dengue virus, the closest relative to ZIKV. These two antibodies provided postexposure protection to mice in vivo. Structural studies revealed that Z23 and Z3L1 bound to tertiary epitopes in envelope protein domain I, II, or III, indicating potential targets for ZIKV-specific therapy. Our results suggest the potential of antibody-based therapeutics and provide a structure-based rationale for the design of future ZIKV-specific vaccines.

PubMed: 27974667
DOI: 10.1126/scitranslmed.aai8336

Experimental method

ELECTRON MICROSCOPY (9.4 Å)